La Jolla Pharmaceutical Company

Get the LJPC Research Report and Also Receive Our Top Trades for 2017! On February 27th, the company announced positive top-line results from the ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) Phase 3 study of LJPC-501 (angiotensin II) in patients...